A novel mechanism for activation of GLI1 by nuclear SMO that escapes anti-SMO inhibitors

Small molecule inhibitors of the Hedgehog (HH) pathway receptor Smoothened (SMO) have been effective in treating some patients with basal cell carcinoma (BCC), where the HH pathway is often activated, but many patients are poorly responsive. In this study, we report the results of investigations on PTCH1 signalling in the HH pathway that suggest why most BCC patients respond poorly to SMO inhibitors. In immortalised human keratinocytes, PTCH1 silencing led to the generation of a compact, holoclone-like morphology with increased expression of SMO and the downstream HH pathway transcription factor GLI1. Notably, while siRNA silencing of SMO in PTCH1-silenced cells was sufficient to suppress GLI1 activity, this effect was not phenocopied by pharmacological inhibition of SMO, suggesting the presence of a second undefined pathway through which SMO can induce GLI1. Consistent with this possibility, we observed increased nuclear localisation of SMO in PTCH1-silenced cells as mediated by a putative SMO nuclear/nucleolar localisation signal (N(o)LS). Mutational inactivation of the N(o)LS ablated this increase and suppressed GLI1 induction. Immunohistological analysis of human and mouse BCC confirmed evidence of nuclear SMO, although the pattern was heterogeneous between tumours. In PTCH1-silenced cells, >80% of the genes found to be differentially expressed were unaffected by SMO inhibitors, including the putative BCC driver gene CXCL11. Our results demonstrate how PTCH1 loss results in aberrant regulation of SMO-independent mechanisms important for BCC biology, and highlights a novel nuclear mechanism of SMO-GLI1 signalling that is unresponsive to SMO inhibitors.

http://ift.tt/2sEq4s2